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Background: Melanocytic proliferations are common in horses but the diagnosis of malignancy is not always
straightforward. To improve diagnosis and prognosis, markers of malignancy are needed. Receptor for activated C
kinase 1 (RACK1) protein may be such a marker. RACK1 was originally found to characterize malignant melanocytic
lesions in the Melanoblastoma-bearing Libechov minipig (MeLiM) and, later, in human patients. Our purpose was to
investigate the value of RACK1 in the classification of cutaneous melanocytic proliferations in horses.
Results: Using immunofluorescence, we report here that both MITF (Microphthalmia-associated transcription factor)
and PAX3 (Paired box 3) allow the identification of melanocytic cells in horse skin samples. Importantly, RACK1 was
detected in melanocytic lesions but not in healthy skin melanocytes. Finally, we found that RACK1 labeling can be
used in horses to distinguish benign melanocytic tumors from melanomas. Indeed, RACK1 labeling appeared more
informative to assess malignancy than individual histomorphological features.
Conclusions: This study confirms that horses provide an interesting model for melanoma genesis studies. It
establishes MITF and PAX3 as markers of horse melanocytic cells. RACK1 emerges as an important marker of
malignancy which may contribute to progress in the diagnosis of melanomas in both human and veterinary
medicine.
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Melanocytic tumors are common in horses. Up to 18%
of all skin tumors are melanocytic [1]. The true inci-
dence may be even higher since a number of epidemio-
logical studies do not include a histological report.
Equine melanocytic tumors may occur in any body area
regardless of age, sex or coat color. Most of these
tumors are clinically benign at initial presentation, but
two-thirds are thought to progress to malignancy and
metastasize [2]. Accordingly, setting a diagnosis on
histopathological analysis alone can be challenging [2].
The term “melanoma” is used for malignant melanocytic
tumors, whereas “melanocytoma” refers to the benign* Correspondence: gegidy@vet-alfort.fr
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distribution, and reproduction in any mediumforms, with the corresponding restrictions. Indeed mor-
phological criteria are not always predictive of clinical
features [1]. In human melanoma, morphology-based
melanoma classification has presented limited clinical
relevance. Nevertheless, Bastian and colleagues have re-
cently shown that clinical and morphologic features
associated with known mutations could be used to iden-
tify biologically related disease groups [3,4]. Coat color
genetic studies in horses identified genes responsible for
associated pathologies [5,6], like melanoma in gray
horses [7]. More studies are needed to determine the
mutation status of horse melanocytic proliferations.
At present, a molecular marker of malignancy would
be of great interest to distinguish benign from malignant
melanocytic tumors. We found that immunodetection of
RACK1 (Receptor for activated C kinase 1) protein
deserves consideration as such a marker. Indeed RACK1
is strongly detected in melanoma cells of primary
tumors and metastases developed in MeLiM minipigs as
well as in human patients. In contrast, RACK1 is nottral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Epidemiological data from horses with the
melanocytic lesions examined
Samples Age Sex Breed Localisation Mitoses
Melanocytoma 1 16 G - trunk None
Melanocytoma 2 - M - trunk None
Melanocytoma 3 5 G Lusitanian under tail None
Melanocytoma 4 - F - trunk None
Melanocytoma 5 10 F - trunk Low
Melanocytoma 6 - M Connemara limb Low
Melanocytoma 7 16 F Connemara trunk Low
Melanocytoma 8 5 F - limb Moderate
Melanocytoma 9 11 M - trunk High
Melanocytoma 10 3 G French
Saddlebred
head Low
Melanocytoma 11 - F - trunk Low
Melanocytoma 12 5 G Appaloosa trunk Low
Melanocytoma 13 - F - trunk None
Melanocytoma 14 7 F French
Saddlebred
head Low
Melanocytoma 15 12 - - limb Low
Melanoma 1 25 - French
Saddlebred
under tail High
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tumoral proliferations [8].
RACK1 is a 36 kDa scaffold protein containing seven
internal WD40 repeats, originally identified as an
anchoring protein for protein kinase C (PKC) [9]. It is
now well established that RACK1 is ubiquitous, with a
tightly regulated expression, and that it interacts with a
large number of proteins. Through its ability to coordin-
ate the interaction of key signaling molecules, RACK1 is
widely perceived as playing a central role in critical bio-
logical responses both in normal cell physiology and in
tumorigenesis [10]. Several in vitro studies have shown
that RACK1 could be implicated in cancer hallmarks
[10-14]. Particularly, there is evidence for a role of
RACK1 in the pathogenesis of melanoma. In the MeWo
human melanoma cell line, RACK1 serves as an adaptor
protein for PKC-mediated JNK (c-Jun NH2-terminal
kinase) activation and increases the survival to UV
induced-apoptosis [15]. RACK1 may allow cross-talks
between several pathways involved in melanoma devel-
opment through the orchestration of protein-protein
interactions.
In this study, we tested the value of RACK1 detection
in the diagnosis of horse melanoma.
Melanoma 2 2 G - trunk High
Melanoma 3 14 M French
Saddlebred
foreskin Low
Melanoma 4 17 M Highland under tail High
Melanoma 5 - M - trunk Moderate
Melanoma 6 - M - under tail Moderate
Melanoma 7 11 G French
Saddlebred
limb Low
Melanoma 8 3 G - trunk Low
Melanoma 9 4 F Anglo-arabian under tail Low
M: Male; F: Female, G: Gelded, -: unavailable data.Methods
Horse (Equus ferus caballus) tissues
Horse tissues were submitted as formalin-fixed excisional
biopsies to the Alfort Veterinary Medicine School
(n = 12), and at the IDEXX Diagnosis Laboratory (n= 27).
Skin samples consisted in previously diagnosed cutane-
ous melanomas (n = 9) or melanocytomas (n= 15)
(Table 1), and in normal glabrous skin (n = 6) from under
the tail area and lips, as well as normal furry skin from
the rump (n = 6), used as control. Tissues that were not
archival diagnostic material were taken at the pro-
grammed euthanasia of individuals used for another
study. Euthanasia had been practiced following recom-
mended consensus publications. Tumors were selected
such that cytological characteristics or vascular emboli
indicated a clear diagnosis. Briefly, dermal or epidermal
proliferations of nests of melanocytes with variable
degrees of pigmentation were considered melanocytomas
when they were well delimited, without or with low
atypia, no mitoses or less than 2 mitoses per ten high
power fields, and no signs of vascular invasion or vascu-
lar embolus. Melanomas were characterized by anisocy-
tosis, anisokaryosis, prominent nucleoli, nuclear atypia or
alternatively tumoral vascular emboli. A high mitotic
index corresponding to more than 10 mitoses per ten
high power fields was also considered a mark of malig-
nancy, however samples with low or moderate mitotic
index could carry other characteristics of malignancy.Age of animals, when available, ranged from 2 to
25 years. In our sampling aged gray horses have a low
representation (Table 1) despite the high incidence of
slow evolving melanocytic tumors in these horses
[16,17].
Immunostaining and ApoTome microscopy
The protocol for immunofluorescence was as previously
described [8] with minor modifications. Briefly, antigen
retrieval was performed in Tris-EDTA, pH 9, for 30 min
in a water-bath. Antibodies were mouse monoclonals
anti-MITF (Zymed, dilution 1:50; Invitrogen, Cergy-
Pontoise, France) anti-RACK1 (Transduction Laborator-
ies, 1:150; BD Biosciences, Le Pont de Claix, France) and
rabbit polyclonals anti- cytokeratin5 (Covance; 1:1000;
Eurogentec, Angers, France) and anti-PAX3 (Zymed;
1:200). Nuclear counter-staining was achieved with 4',
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Sections were examined with a Zeiss Axio Observer
Z1M ApoTome microscope (Carl Zeiss S.A.S. ; Le Pecq,
France). Controls without the first antibodies showed no
unspecific labeling. Images were processed with the
AxioVision computer program version 4.6 (Carl Zeiss).
Figures are representative of the skin samples evaluated.
All images shown are individual sections of z series
stack. Final figures were assembled with Adobe Photo-
shop CS3 (Adobe Systems; USA).Analysis of RACK1 staining distribution
RACK1 staining distribution was analyzed at the tissular
and cellular levels. Distribution within the cytoplasm
was graded 0 when homogeneous and 1 when heteroge-
neous. Samples were graded blindly without reference to
pathology reports.Figure 1 PAX3 and MITF immunolabeling in horse skin and cutaneou
melanocytoma, (3) cutaneous melanoma (A): PAX3 protein immunolabelin
nuclear PAX3 labeling is identified in melanocytes (arrows) and melanocyti
immunolabeling (red) with corresponding bright-field photographs (D). A s
control skin and lesions (C1-C3) with very low background. Nuclear counte
dermis boundary. e, epidermis; d, dermis. Magnification is the same in all imAnalysis of elementary histological features
All histopathological evaluations were carried out on
routinely stained hematoxylin-eosin-safran sections. The
size of the tumors was missing in some clinical files; the
dimensions of the lesions on histological sections ranged
from 4 to 80 mm. To highlight the histological specificity
of horse melanomas and melanocytomas, all tissue sec-
tions were examined at 3 different magnifications (10, 20,
40 high power field) and classified according to the eleven
histo-morphometric criteria previously defined by Viros
et al. [4]: scatter of intraepidermal melanocytes, nest for-
mation of intraepidermal melanocytes, cytoplasmic pig-
mentation of neoplastic melanocytes, size and shape of
cells, nuclei and nucleoli, epidermal contour, lateral cir-
cumscription, thickness of normal epidermis and presence
of ulceration. Grading was carried out like in Viros et al.
[4] except for ulceration which was graded 0 for absence
and 1 for presence. The samples were graded blindlys melanocytic proliferations. (1) control horse skin, (2) cutaneous
g (green) with corresponding bright-field photographs (B). A specific
c cells (A1-A3) with low background signal. (C): MITF protein
pecific nuclear MITF labeling is observed in melanocytic cells in
rstaining is shown in blue. Dotted lines (A1 and C1) indicate epidermis-
ages, bar: 10 μm.
Figure 2 RACK1, CK5 and MITF immunolabelings in horse skin.
RACK1 protein labeling (green), MITF (red) and CK5 (magenta) in
control horse skin. Cytoplasm of basal keratinocytes is positive for
CK5 signal and RACK1 (B). Melanocytes are positive for MITF, but
negative for CK5 and RACK1 (A, B). Dotted line indicates epidermis-
dermis boundary. e, epidermis; d, dermis. Bar: 10 μm.
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reports, Two groups –melanomas and melanocytomas–
were subsequently made based on these reports. Sections
were observed with a Leica DMLB microscope (Leica
Microsystems S.A.S., Nanterre, France). Images were pro-
cessed with the MetaVue Imaging System (Molecular
Devices; St Grégoire, France) computer program. Histo-
logical pictures were taken with AxioImager.ZI through a
AxioCam HRc camera and processed with the AxioVision
4.6.3 SPI software (Carl Zeiss).
Statistical analysis
Statistical differences between means taken in pairs were
evaluated by Student’s t test. The test was adapted for a
number of samples below 30 [18]. A P-value <0.05 was
considered as statistically significant.
Results
MITF is a sensitive marker to identify melanocytic cells in
horses
In order to analyze melanocytic proliferations, we first
needed a marker to identify melanocytic cells within tis-
sue sections. Both MITF and PAX3 transcription factors
are expressed by melanocytes and their precursors
[19,20]. Comparison of horse and human protein
sequences for MITF and PAX3 resulted in more than
90% identity. On tissue sections, melanocytes at the
basal layer of healthy skin were labeled by a specific nu-
clear signal using a rabbit PAX3 antibody (Figure 1 A1)
or a mouse MITF antibody (Figure 1 C1). Unspecific la-
beling was not detected (not shown). Moreover, MITF
and PAX3 are expressed by melanocytic cells within
tumoral proliferations [8,21]. PAX3 and MITF-positive
cells were identified both in melanocytomas and in mel-
anomas regardless of the pigmentation of the lesion
(Figure 1 A2, A3, C2, C3). Both MITF and PAX3 anti-
bodies proved to be helpful in identifying the melanocytic
lineage in horse tissues. Nevertheless, MITF antibody
detected the nucleus of melanocytic cells with more sen-
sitivity than did the PAX3 antibody. MITF antibody was
thus used for further analyses.
RACK1 protein distinguishes melanoma from
melanocytoma, but also from normal melanocytes in
horses
We analyzed the tissue and cellular distribution of
RACK1 protein, in healthy skin and melanocytic lesions,
after double immunostaining for RACK1 and MITF. In
healthy control skins (n = 12), RACK1 protein was highly
expressed in the cytoplasm of keratinocytes which
were used as positive controls (Figure 2A). By contrast,
MITF-positive melanocytes were negative for RACK1
(Figure 2A). Triple immunostaining against RACK1,
MITF and cytokeratin 5 (CK5), a marker of basal
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the cell type containing RACK1 in the epidermis. Every
signal for RACK1 in the vicinity of melanocytes coloca-
lized with CK5 (Figure 2B). Thus, in these labeling condi-
tions, RACK1 was not detected in horse normal
melanocytes.
In all melanocytic lesions examined (n = 24), RACK1
was extensively detected in MITF-positive cells, with two
distinct distribution patterns. RACK1 was distributed ei-
ther heterogeneously (Figure 3A) or homogeneously over
the lesion, whether tumors were pigmented or not
(Figure 3B, 3C). In lesions with heterogeneous distribu-
tion, RACK1 was detected as a granular cytoplasmic
staining in melanocytic cells. In sharp contrast, in lesions
with homogeneous distribution, RACK1 staining was dif-
fuse, perinuclear and cytoplasmic (compare Figure 3A
with Figure 3B and 3C). We tested whether theFigure 3 RACK1 and MITF immunolabelings in cutaneous melanocytic
RACK1 in green. (A) melanocytoma, (B) melanoma, (C) achromic melanom
(A1 and A2). Arrowheads point to melanocytic cells that express variable am
(B1 to C2), all MITF-positive cells display a strong and homogeneous cytop
Corresponding bright-field photographs are presented (A3 to C3). Magnificcytoplasmic distribution of RACK1 staining could be of
help in classifying melanoma lesions. For this purpose
the distribution of RACK1 was graded 0 when
homogenous, and 1 when heterogeneous. Samples were
graded independently by two of us, blindly without refer-
ence to pathology reports. Subsequently, melanocytoma
and melanoma samples were grouped based on path-
ology reports. Comparison of RACK1 grading between
the two groups resulted in a statistical difference (1 ± 0
vs. 0.2 ± 0.36 respectively; P< 0.001). All samples histolo-
gically classified as melanocytomas (n = 15) stained het-
erogeneously for RACK1. Among melanomas (n = 9),
two samples also stained heterogeneously for RACK1
(data not shown). Noteworthy, these two melanomas had
several characteristics of low histopathological aggres-
siveness, which was low mitotic rate and no vascular em-
bolisation but high anisokaryosis. All other melanomaproliferations from horses. MITF labeling is shown in red and
a. In melanocytoma, RACK1 cytoplasmic expression is heterogeneous
ounts of RACK1. By contrast, in pigmented or achromic melanoma
lasmic RACK1 signal (B2, C2). Nuclear counterstaining is shown in blue.
ation is the same in all images, scale bar represents 10 μm.
Figure 4 Variability of histological features of horse melanomas and uniformity of RACK1/MITF labeling. (A-B): Sections of two different
melanomas with hematoxylin-eosin-safran staining, with their respective low magnification in the inserts. Note the variability in pigmentation
between tumors (A, B) and in different areas of the same tumor (A1, A2). (C): Histological staining of a pigmented area from A with ovoid and
spindled cells (C1), and low power capture of RACK1 (green) - MITF (red) labeling in the adjacent section (C2), (C3) bright-field corresponding to
C2. Note RACK1 signal uniformity in the different areas. Bar: 50 μm.
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plasmic RACK1 labeling may be helpful in distinguishing
melanoma from benign melanocytic skin tumors.RACK1 detection is more informative than individual
histomorphological features
Melanocytic lesions in our samples displayed a large
histological variety. Figures 4A and 4B show various pig-
mentation patterns and cell shapes in two representative
melanomas. Interestingly enough, RACK1 distribution
pattern was constant throughout the whole of the
lesions, as illustrated in Figure 4C. To better characterize
the lesions, we performed a detailed analysis based on
the morphological criteria Bastian’s group used on
human samples [4], summarized in Table 2. We found
that equine melanomas were characterized by: high pig-
mentation (Table 2, 2nd column), abrupt lateral circum-
scription (Table 2, 4th column) at the transition from
involved area to adjacent normal tissue (Figure 4A) and a
thicker epidermal contour (Table 2, 5th column), indica-
tive of epidermal hyperplasia. Moreover, we often
observed an absence of junctional component, as previ-
ously described [17]. However none of these characteris-
tics reached statistical significance when compared to
those of melanocytomas. Finally, we checked every mor-
phological criterion and the RACK1 distribution pattern
against the malignancy status. RACK1 signal pattern of
distribution was more frequently indicative of malig-
nancy than any single morphological criterion, pointing
out its usefulness as a diagnostic marker.Discussion
Early identification of malignant melanocytic lesions is
crucial for patient survival in human and veterinary
medicine. RACK1 is a scaffold protein found to integrate
various metabolic pathways involved in tumorigenesis
[22,23]. It was proposed as a marker of malignancy in
pig and human melanomas [8]. We extend these obser-
vations to melanomas in horses which displayed an over-
expression of RACK1 when compared to normal
cutaneous melanocytes.
In an attempt to find a more refined morphological clas-
sification to distinguish benign from malignant lesions, we
used the criteria defined for human melanoma in equine
melanocytomas and melanomas. Although none of the
morphological criteria taken separately were powerful
enough to distinguish between benign and malignant tis-
sue, we highlight specific histological features of equine
melanoma that recapitulate those seen in atypical rare
forms of human malignant nævi and melanomas such as
pigment synthesizing melanoma, desmoplastic melan-
oma, primary dermal melanoma, and malignant blue
nævus [24-27]. This makes the study of equine melan-
oma a source of information to understand development
of atypical melanoma in mammals.
We show that PAX3 and MITF immunolabeling can
be used to identify melanocytes as well as melanocytic
transformed cells within a tumor bulk. MITF is known
to mark melanocytic proliferations in humans and pigs
[8]. More specifically, we show that PAX3 is expressed
by mature melanocytes in horses, as in humans [21]. In
every sample from healthy and tumoral tissues, the
Table 2 Histomorphological features and RACK1 pattern in horse melanocytic lesions















1 3 4 3 - - 3 0.5 2 - - 0 1
2 - 4 0 - - 2 1 1 - 1 - 1
3 0 1 2 2 2 2 2 2 1 1 0 1
4 1 3 3 1 4 1.5 3 3 1.5 1 1 1
5 1 3.5 0 2 2 2 1 1 0 1 0 1
6 3 4 1 1 2 3 0.5 2 0 1 1 1
7 1 2 2 0 2 3 0 3 0 1 0 1
8 0 1 1 2 2 3 1.5 2.5 1.5 3 0 1
9 0 3 1 0 2 3 1 2 0 1 0 1
10 2 3 1 1 2 2 1.5 3 0 1 0 1
11 1 4 0 1 3 2.5 2.5 1 1 1 0 1
12 0 3.5 0 0 2 3 1.5 2 0 1 1 1
13 2 4 0 2 3 1 2 3 0 1 0 1
14 1 4 2.5 0 2 2.5 1.5 2 0 1.5 0 1
15 - 4 0 1 0 2 1.5 2 0 1 1 1
Melanomas
1 3 2 3 1 - 3 1 3 - 3 1 0
2 3 4 2 2 3 3 2.5 3 0 1 0 0
3 2 1 1 2 4 2 2.5 3 2 1 1 0
4 - 1 0 1 - 3 1 3 0 3 0 0
5 3 4 1 1 1 3 1 3 0 2.5 1 0
6 1 4 1 2 3 2 2 3 1.5 2 0 0
7 1 4 3 2 2 3 1 2.5 - 2 0 1
8 0 3 0 2 2 3 1 3 0 2.5 0 1
9 2 3 2 1 3 3 3 3 1 3 0 0
aScatter of intraepidermal melanocytes: 0, absent; 1, slight; 2, medium; 3, prominent.
bCytoplasmic pigmentation of neoplastic melanocytes: 0,absent; 1, slight; 2, medium; 3, high; 4, very high.
cNesting of intraepidermal melanocytes: 0, absent; 1, slight; 2, medium; 3, prominent.
dLateral circumscription: 0, discontinuous; 1, continuous; 2, abrupt.
eEpidermal contour: 0, atrophy; 1, effacement; 2, normal; 3, thickening; 4, hyperplasia.
fCell size: 1, small; 2, medium; 3, large.
gCell shape: 0, round; 1, ovoid; 2, elongated; 3, spindled.
hNuclear size: 1, small; 2, medium; 3, large.
iNuclear shape: 0, round; 1, ovoid; 2, elongated; 3, spindled.
jNucleolar size: 1, small; 2, medium; 3, large.
kUlceration: 0, absent; 1, present.
lRACK1 distribution pattern: 0, homogenous; 1, heterogenous.
-: Impossible evaluation.
x.5: means of two different authors observations.
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beling. Achromic tumoral samples were also positively
stained for MITF. We therefore propose MITF immuno-
labeling as a diagnosis marker for melanocytic tumors in
horses.
All the samples identified as melanocytomas by histo-
pathologic analysis stained heterogeneously for RACK1.
On the other hand, a homogeneous staining for RACK1
only appeared on melanomas. Two samples identified asmelanomas also stained heterogeneously for RACK1.
Both had morphological characteristics of low aggres-
siveness as a low mitotic index. This is a common pitfall
in histological analysis of equine melanoma, and reports
on antigens related to the cell cycle gave controversial
results [17,28]. However, no classification based on
detailed staging [29] is available for equine melanomas.
We extended previous observations on RACK1 expres-
sion in melanoma from humans and pigs to melanocytic
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bution of RACK1 reflects melanoma progression and
aggressiveness: the more homogenous and diffuse the
cytoplasmic RACK1 labeling is, the more aggressive the
melanoma. Thus, we propose RACK1 as a marker of
malignancy in equine melanocytic proliferations.
Furthermore, our data show that the cellular distribution
pattern of RACK1 on melanocytes in tumors, i.e.
homogenous if malignant and heterogeneous if benign, is
constant throughout the whole lesion. RACK1 distribution
pattern analyzed in a punch biopsy appears as informative
for diagnosis and less invasive than a complete biopsy. This
is a particularly interesting element since skin biopsies in
horses are not that easy to carry out. A quick grading could
influence on the decision of treating melanomas more ur-
gently, even if they are less suited for surgical therapies.
In domestic animals, veterinary pathologists use the
term melanocytomas to describe benign melanocytic
tumors [30]. In humans, such benign melanocytic tumors
are designated as nævi and the term melanocytoma is sel-
dom used. It defines melanocytic tumors with uncertain
malignancy status [31,32]. Our data show that the distri-
bution of RACK1 labeling is heterogeneous in horse mela-
nocytomas while it is absent or faint in human nævi [8].
This confirms the difference between melanocytomas and
nævi at the molecular level. In horses, the second most
common clinical presentation of melanoma is the malig-
nant transformation of a melanocytoma [33]. Based on
RACK1 distribution, we hypothesize that horse melanocy-
tomas may be premalignant entities ready to switch to
malignancy. RACK1 detection would reveal this switch to
malignancy, if any.
Conclusions
RACK1 protein was detected with intense, diffuse and
homogenous staining in MITF-positive cells of equine
melanomas. This observation is consistent with stainings
in human melanomas and MeLiM minipig melanocytic
tumors. We now confirm the usefulness of RACK1 label-
ing as a diagnosis marker for melanoma. The homogenous
distribution pattern of RACK1 signal shared by human,
pig, and horse melanomas strongly suggests a function for
RACK1 in melanoma progression in mammalian skin.
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